News

TORONTO, October 29, 2004 (LifeSiteNews.com) – Embryonic stem cell therapy requires cloning and for this and other reasons such therapy will be a “rich man’s treatment” which creates a very big industry and huge potential profits. That, says Australian medical doctor, bioethicist and lecturer at the University of New South Wales, Dr. Amin Abboud, is the reason for the big push for embryonic stem cell research and cloning.  LifeSiteNews.com interviewed the dynamic, typically Austalian, young doctor at the office of Campaign Life Coalition in Toronto on September 25, while he was on a one day stopover on the way back to Australia from conferences in Europe. Abboud answered questions on bioethics, embryonic stem research and cloning using simple terminology and examples that could be easily followed by almost anyone.  See the rest of this LIFESITENEWS.COM SPECIAL REPORT at:  https://www.lifesitenews.com/ldn/2004/oct/041029a.html

Comments

Commenting Guidelines

LifeSiteNews welcomes thoughtful, respectful comments that add useful information or insights. Demeaning, hostile or propagandistic comments, and streams not related to the storyline, will be removed.

LSN commenting is not for frequent personal blogging, on-going debates or theological or other disputes between commenters.

Multiple comments from one person under a story are discouraged (suggested maximum of three). Capitalized sentences or comments will be removed (Internet shouting).

LifeSiteNews gives priority to pro-life, pro-family commenters and reserves the right to edit or remove comments.

Comments under LifeSiteNews stories do not necessarily represent the views of LifeSiteNews.